Dabrafenib, trade name Tafinlar, is a drug for the treatment of cancers associated with a mutated version of the gene BRAF - especially skin cancer. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a safety profile in patients with BRAF(V600)-mutated metastatic melanoma.
Model release not required. Property release not required.